Related Experiment Video

Updated: Mar 26, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors

E A Sokolova1, O A Stremovskiy2, T A Zdobnova3

  • 1Lobachevsky State University of Nizhny Novgorod, pr. Gagarina 23, 603950, Nizhny Novgorod, Russia ; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, 117997, Moscow, Russia.

Acta Naturae
|January 23, 2016
PubMed

Insights

A new recombinant immunotoxin targeting the HER2 tumor marker shows high affinity and selective cancer cell killing. This targeted therapy agent, 4D5scFv-PE40, demonstrates potential for effective in vivo cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Recombinant immunotoxins offer targeted cancer therapy for tumors with specific molecular profiles.
  • The HER2 tumor marker is a target for developing novel cancer treatments.

Purpose of the Study:

  • To investigate the properties of a novel recombinant HER2-specific immunotoxin, 4D5scFv-PE40.
  • To evaluate the affinity, cytotoxicity, and stability of 4D5scFv-PE40 for potential therapeutic applications.

Main Methods:

  • Construction and characterization of the 4D5scFv-PE40 immunotoxin.
  • Assessment of binding affinity to the HER2 tumor marker.
  • Evaluation of selective cytotoxicity against HER2-overexpressing cancer cells in vitro.
  • Comparison of efficacy with free Pseudomonas exotoxin A (PE40).

Main Results:

  • The 4D5scFv-PE40 immunotoxin exhibited high affinity for the HER2 tumor marker.
  • Demonstrated selective cytotoxicity against HER2-overexpressing cancer cells, with IC50 values 2.5-3 orders of magnitude lower than non-expressing cells.
  • Showcased significantly lower IC50 compared to free PE40 in HER2-overexpressing cells.
  • Confirmed storage stability of the immunotoxin.

Conclusions:

  • 4D5scFv-PE40 is a potent HER2-specific immunotoxin with selective anti-cancer activity.
  • The findings support the potential for a high therapeutic index, suggesting efficacy for in vivo applications.
  • This recombinant immunotoxin represents a promising candidate for targeted cancer therapy.
Keywords:
4D5scFvHER2 tumor markerPseudomonas exotoxin Arecombinant immunotoxintargeted therapy

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.7K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K